Purpose: To describe the survival and toxicity outcome from a single-centre experience in patients with squamous cell cancer of the anal canal SCC-AC , related to the impact of technological advances in diagnostics and radiation techniques. Material and Methods: A retrospective cohort study was performed after the approval of the institutional ethical committee EK We identified patients in our registry, who received radical treatment for SCC-AC between and Acute and late toxicities were also reported.
Results: At a median follow-up of The use of IMRT was associated with shorter treatment duration. In the multivariate analysis, IMRT was associated with the improvement of all survival paraments. Grade-3 and more dermatological toxicities occurred less frequently, but hematological toxicities were more frequent in the IMRT-group.
Late side effects and colostomies were less frequently reported in the IMRT group. Conclusion: The use of IMRT in the management of SCC-AC was associated with improvement of the oncological outcomes with improved toxicity profiles in this long-term single-centre experience. Anal cancer is a rare disease with new cases diagnosed in in Germany, accounting for 0. With deaths, anal cancer contributes with 0.
Fisch et al. Other risk factors include HIV infection, the history of anal intercourse, and organ transplant recipients 3.
Radiotherapy with concomitant chemotherapy CRT with fluoropyrimidines 5-FU and Mitomycin c MMC is the primary treatment modality for patients with invasive anal cancer. This paradigm has not changed markedly since when Nigro et al. The replacement of MMC with Cisplatin to spare hematological toxicities has been evaluated in two trials.
